1. A 68-year-old woman with end-stage renal disease (ESRD) on hemodialysis three times weekly is being treated for metastatic breast cancer with bone pain. She has been maintained on oral morphine 30 mg every 4 hours for two months with adequate analgesia. Over the past three weeks she has developed new-onset myoclonic jerks, worsening confusion, and paradoxically increasing pain despite no change in her morphine dose. Her nephrologist confirms her dialysis adequacy is unchanged. Which of the following most accurately explains her clinical deterioration and identifies the correct next step?
A) Her symptoms represent opioid tolerance from two months of continuous morphine exposure; the correct next step is to increase the morphine dose by 25–30% and reassess pain control within 48 hours, as tolerance-related worsening typically responds to dose escalation
B) Her symptoms represent morphine-6-glucuronide (M6G) accumulation causing excessive mu-opioid receptor (MOR) activation at cortical and spinal sites, producing sedation and paradoxical pain through MOR overstimulation; the correct next step is naloxone administration to reverse M6G-mediated MOR excess
C) Her symptoms represent accumulation of unchanged parent morphine from reduced renal clearance; hemodialysis removes morphine efficiently, but interdialytic morphine accumulation between sessions explains the episodic nature of her symptoms; the correct next step is to time morphine doses to dialysis sessions
D) Her worsening pain, myoclonus, and confusion represent accumulation of morphine-3-glucuronide (M3G) — a neuroexcitatory, pro-nociceptive metabolite that accumulates in renal failure and opposes morphine's analgesic effect — combined with accumulating morphine-6-glucuronide (M6G), a potent MOR agonist causing opioid toxicity; the correct next step is to discontinue morphine and transition to fentanyl, whose CYP3A4-mediated metabolism to inactive norfentanyl produces no renally cleared toxic metabolites
E) Her symptoms represent dialysis disequilibrium syndrome causing transient neurological dysfunction that mimics opioid toxicity; morphine dosing is unrelated to her neurological symptoms, and the correct next step is to adjust her dialysis parameters rather than change her analgesic regimen
ANSWER: D
Rationale:
This question asked you to identify the mechanism of clinical deterioration in an ESRD patient on chronic morphine and determine the correct management. Option D is correct. Morphine undergoes hepatic glucuronidation to two major metabolites with opposing pharmacological activities. Morphine-3-glucuronide (M3G) is neuroexcitatory and pro-nociceptive — it acts at glycine and GABA-A receptors to produce excitation rather than inhibition, causing myoclonus, cognitive impairment, hyperalgesia, and allodynia, and paradoxically worsening pain by opposing morphine's analgesic effect at the spinal level. Morphine-6-glucuronide (M6G) is a potent MOR agonist with analgesic and respiratory depressant activity exceeding morphine itself on a molar basis, and accumulates in renal failure to cause prolonged opioid toxicity. Both metabolites are renally cleared and accumulate progressively as eGFR declines; in ESRD on hemodialysis, this accumulation is persistent because hemodialysis does not efficiently clear these highly protein-bound metabolites between sessions. The triad of myoclonus, confusion, and paradoxically worsening pain in an ESRD patient on stable morphine is the clinical signature of this dual metabolite toxicity. Fentanyl is the correct alternative because CYP3A4 (cytochrome P450 3A4)-mediated hepatic metabolism produces norfentanyl, an inactive metabolite without meaningful renal clearance, directly eliminating the accumulation mechanism.
Option A: Option A is incorrect because the symptom triad — myoclonus, confusion, paradoxically worsening pain — is not consistent with opioid tolerance, which produces reduced analgesic effect without neuroexcitatory features; dose escalation in this patient would worsen M3G and M6G accumulation and deepen the toxicity.
Option B: Option B is incorrect because while M6G does accumulate and contributes to the opioid toxicity component, it is M3G accumulation that produces the neuroexcitatory features and paradoxical worsening of pain; naloxone would address the M6G-mediated opioid toxicity component but would not reverse the M3G-mediated neuroexcitation, and the definitive solution is agent substitution.
Option C: Option C is incorrect because unchanged parent morphine is not the accumulating species causing toxicity in ESRD; morphine is extensively hepatically metabolized, and the renal failure problem is metabolite accumulation, not parent drug accumulation. Additionally, hemodialysis does not reliably clear M3G and M6G.
Option E: Option E is incorrect because dialysis disequilibrium syndrome produces neurological symptoms during or immediately after dialysis through rapid osmolality shifts; it does not produce the subacute worsening over three weeks described, and does not cause myoclonus with paradoxically worsening pain in the clinical pattern described.
2. A 74-year-old man has had postherpetic neuralgia (PHN) affecting the right thoracic dermatome for eight months following herpes zoster. He failed gabapentin and the 5% lidocaine patch and was started on oxycodone extended-release 20 mg twice daily four months ago with initial good pain control. Over the past six weeks his pain has worsened from 4/10 to 8/10, and he now reports diffuse burning throughout his trunk and bilateral lower extremities — well beyond his original right thoracic distribution. He has required two dose increases without improvement. Quantitative sensory testing shows markedly lowered pain thresholds to mechanical stimuli across all tested sites. Which of the following most accurately identifies his current condition and guides the next management step?
A) The diffuse spread of pain beyond the original PHN distribution, worsening despite opioid dose escalation, and generalized lowering of pain thresholds across unaffected body regions are hallmarks of opioid-induced hyperalgesia (OIH) — a state of paradoxical pain sensitization driven by chronic opioid-induced N-methyl-D-aspartate (NMDA) receptor activation and upregulation of pronociceptive central pathways; the correct next step is opioid dose reduction or rotation to a different opioid (with or without addition of an NMDA antagonist such as low-dose ketamine or methadone), not further dose escalation
B) The worsening pain and spread beyond the original dermatomal distribution represent varicella-zoster virus (VZV) reactivation in additional dermatomes — a recognized complication of PHN in elderly immunosenescent patients; the opioid regimen is appropriate but insufficient for the expanded pain territory, and the correct next step is antiviral therapy with valacyclovir combined with opioid dose escalation to cover the additional affected areas
C) The clinical picture represents opioid tolerance that has developed over four months of continuous oxycodone therapy; the generalized lowering of pain thresholds reflects PHN-related central sensitization that was previously suppressed by opioid therapy but is now unmasked as tolerance develops; the correct next step is a 40–50% opioid dose increase to overcome tolerance and re-establish central sensitization suppression
D) The diffuse pain spread and lowered pain thresholds represent progression of PHN to involve the spinal cord through ascending VZV infection — a rare but recognized complication called VZV myelitis; the correct next step is MRI of the thoracic and lumbar spine followed by intravenous acyclovir, with opioid therapy continued at current doses pending the diagnostic evaluation
E) The worsening pain despite opioid dose escalation confirms that oxycodone is ineffective for PHN specifically because its CYP2D6-dependent conversion to oxymorphone is impaired by age-related CYP2D6 decline; the correct next step is to switch to morphine, which does not require CYP2D6 activation and will provide full opioid analgesia that oxycodone cannot deliver in elderly patients
ANSWER: A
Rationale:
This question asked you to distinguish opioid-induced hyperalgesia (OIH) from opioid tolerance and identify the correct clinical response. Option A is correct. The clinical picture is the textbook presentation of OIH: pain that worsens despite opioid dose escalation, spreads well beyond the original pain distribution (from a right thoracic dermatome to bilateral trunk and lower extremities), and is accompanied by generalized lowering of pain thresholds across unaffected body regions on quantitative sensory testing. This pattern is mechanistically explained by chronic opioid-induced activation of NMDA receptor-mediated central sensitization and upregulation of pronociceptive descending facilitation from the rostral ventromedial medulla (RVM) — pathways that amplify pain perception throughout the neuraxis rather than in the original injured territory. The critical clinical implication is that further dose escalation worsens OIH by driving further NMDA receptor-mediated central sensitization; the correct response is dose reduction (which allows the central sensitization to resolve) or opioid rotation (to a different opioid, since cross-sensitization is incomplete), potentially with an NMDA receptor antagonist (ketamine, or methadone for its dual MOR agonism and NMDA antagonism) to actively attenuate the central sensitization. This presentation is distinct from opioid tolerance, in which reduced analgesic effect does not spread beyond the original pain territory and pain thresholds outside the original pain area do not change.
Option B: Option B is incorrect because multidermatomal VZV reactivation does not produce the bilateral symmetric sensory sensitization described by quantitative sensory testing, and the timeline and pattern of worsening — progressive with each opioid dose increase — is pharmacodynamic rather than virological in character.
Option C: Option C is incorrect because opioid tolerance produces reduced analgesic effect within the original pain territory, not diffuse spread of pain to uninvolved body regions; generalized lowering of pain thresholds across unaffected sites is not a feature of tolerance and is the key discriminating feature of OIH.
Option D: Option D is incorrect because VZV myelitis is an acute complication of primary VZV reactivation, not a subacute progressive complication of established PHN four months after the acute episode, and does not produce the bilateral symmetric sensory sensitization pattern described.
Option E: Option E is incorrect because age-related CYP2D6 decline is not established as a clinically significant cause of oxycodone therapeutic failure in elderly patients; oxycodone itself has direct MOR agonist activity independent of its CYP2D6-mediated conversion to oxymorphone, and the pharmacokinetic explanation does not account for the spread of pain beyond the original distribution.
3. A 55-year-old woman is maintained on methadone 90 mg/day through an opioid treatment program for opioid use disorder (OUD). Her baseline ECG shows a QTc of 468 ms. She is admitted to hospital for invasive candidiasis and started on intravenous fluconazole 400 mg/day. On hospital day 3 a repeat ECG shows QTc of 512 ms. She is asymptomatic. Which of the following correctly identifies the two pharmacological mechanisms responsible for the QTc prolongation and guides the most appropriate next step?
A) The QTc prolongation results from fluconazole's direct cardiotoxicity through inhibition of cardiac Na/K-ATPase, which reduces intracellular potassium and prolongs the cardiac action potential independently of methadone; methadone contributes no additional QTc effect because its hERG channel blockade requires plasma concentrations above 1000 ng/mL, which therapeutic doses do not achieve; the correct next step is to discontinue fluconazole and substitute an echinocandin antifungal
B) The QTc prolongation is entirely attributable to the stress response of invasive infection, which elevates circulating catecholamines and prolongs cardiac repolarization through beta-1 adrenoceptor-mediated effects on ion channel kinetics; methadone and fluconazole contribute no direct pharmacological QTc effect; the correct next step is treatment of the underlying infection without antifungal or methadone dose changes
C) Fluconazole is a potent CYP3A4 inhibitor that reduces methadone's hepatic clearance, raising plasma methadone concentrations and increasing its hERG (IKr) channel-blocking activity; fluconazole also independently prolongs the QTc through its own hERG channel blockade; these two mechanisms combine additively to produce the observed QTc prolongation from 468 ms to 512 ms; the correct next steps include cardiology consultation, continuous cardiac monitoring, electrolyte optimization, consideration of methadone dose reduction, and evaluation of whether fluconazole can be substituted with an antifungal agent with less QTc and CYP3A4 interaction burden
D) The QTc prolongation from 468 ms to 512 ms represents a benign pharmacological interaction with no clinical significance because QTc values below 550 ms never produce torsades de pointes (TdP) in patients without underlying structural heart disease; the correct next step is to continue both methadone and fluconazole without any monitoring change and reassess the ECG at discharge
E) The QTc prolongation results from fluconazole inhibiting CYP2D6-mediated methadone metabolism, causing parent methadone accumulation; because methadone's QTc effect is dose-independent and occurs through a receptor-mediated mechanism rather than channel blockade, dose reduction will not reduce the QTc prolongation; the correct next step is to discontinue methadone entirely and transition the patient to buprenorphine, which does not prolong the QTc
ANSWER: C
Rationale:
This question asked you to identify the two pharmacological mechanisms driving QTc prolongation in a patient on methadone started on fluconazole, and determine appropriate management. Option C is correct. Two distinct and additive mechanisms explain the QTc increase from 468 ms to 512 ms. First, fluconazole is a potent inhibitor of CYP3A4 (the primary enzyme for methadone metabolism) and also inhibits CYP2C9 and CYP2C19; CYP3A4 inhibition reduces methadone's hepatic clearance, causing plasma methadone concentrations to rise above the steady-state level established on the prior stable dose. As plasma methadone concentrations increase, its hERG (IKr) channel-blocking activity increases proportionally, further prolonging cardiac repolarization. Second, fluconazole itself independently blocks hERG channels and prolongs the QTc through its own direct cardiac effect — a well-characterized azole antifungal class effect. These two mechanisms — pharmacokinetic elevation of methadone concentrations and pharmacodynamic hERG blockade by fluconazole — combine additively in a patient whose baseline QTc of 468 ms already exceeds the threshold of concern (450 ms in women). A QTc of 512 ms represents a substantially elevated risk of torsades de pointes (TdP), particularly in the context of two concurrent hERG-blocking agents. Appropriate next steps include cardiac monitoring, electrolyte optimization (ensuring normal potassium and magnesium), consultation regarding methadone dose reduction, and evaluation of whether an antifungal with less CYP3A4 and QTc interaction burden (such as an echinocandin for susceptible candida species) can be substituted.
Option A: Option A is incorrect because fluconazole does not produce cardiac effects through Na/K-ATPase inhibition; its cardiac mechanism is hERG channel blockade, and methadone does produce clinically meaningful hERG blockade at therapeutic plasma concentrations — not only at concentrations above 1000 ng/mL.
Option B: Option B is incorrect because catecholamine-mediated beta-1 adrenoceptor effects do not produce the magnitude of QTc prolongation seen here, and the direct pharmacological contributions of both methadone (hERG blockade) and fluconazole (CYP3A4 inhibition + hERG blockade) are well established and cannot be attributed to infection stress.
Option D: Option D is incorrect because a QTc of 512 ms in a patient on two QTc-prolonging drugs with interacting pharmacokinetics is not clinically benign; TdP risk increases substantially above 500 ms, and the 550 ms threshold cited as a safety boundary is not established in clinical pharmacology — risk is continuous and substantially elevated at 512 ms in this context.
Option E: Option E is incorrect because fluconazole is not primarily a CYP2D6 inhibitor — it is a potent CYP3A4 inhibitor; and methadone's QTc effect is concentration-dependent hERG channel blockade (not receptor-mediated and not dose-independent), meaning that dose reduction does reduce QTc prolongation. Discontinuing methadone entirely and transitioning to buprenorphine during an acute invasive candidiasis hospitalization is not appropriate urgent management.
4. A 48-year-old man with pancreatic cancer, alcoholic cirrhosis (Child-Pugh Class B), and diabetic nephropathy (eGFR 28 mL/min/1.73m²) presents with severe cancer-related pain rated 9/10. He has not previously received opioids. His oncologist needs to initiate opioid analgesia. Which of the following opioid selection and initial dosing strategy correctly applies both his hepatic and renal pharmacokinetic constraints?
A) Morphine is the appropriate first-line agent because its well-characterized dose-response relationship allows precise titration in opioid-naive patients; the Child-Pugh Class B cirrhosis is managed by reducing the dose by 30% from standard, and the eGFR 28 mL/min/1.73m² is managed by extending the dosing interval to every 6 hours; these two adjustments together adequately prevent both hepatic accumulation and renal metabolite toxicity
B) Fentanyl is the most appropriate agent because CYP3A4-mediated hepatic metabolism to inactive norfentanyl produces no renally cleared toxic metabolites — directly addressing the eGFR 28 mL/min/1.73m² constraint — while the Child-Pugh Class B hepatic impairment requires initiating at a conservative dose with extended titration intervals to account for reduced CYP3A4 clearance, increased oral bioavailability from reduced first-pass extraction, and increased free drug fraction from reduced protein synthesis; both constraints are addressable within a single agent through careful dose titration
C) Hydromorphone is the preferred agent because its analgesic potency is higher than morphine on a milligram-per-milligram basis, allowing smaller absolute doses that minimize both hepatic metabolic burden and renal metabolite load; the H3G metabolite's prolonged accumulation in renal failure provides sustained analgesia that reduces dosing frequency, which is advantageous in a patient with both organ impairments
D) Methadone is the preferred agent because its fecal excretion pathway eliminates the renal metabolite accumulation concern, and its NMDA receptor antagonist activity provides additional analgesic benefit in cancer pain with a neuropathic component; standard methadone doses require no adjustment in Child-Pugh Class B cirrhosis because CYP3A4 impairment is only clinically significant in Child-Pugh Class C
E) Codeine is the preferred opioid in this patient because it is a prodrug that requires hepatic CYP2D6 activation; in a patient with hepatic impairment, reduced CYP2D6 activity limits the conversion of codeine to active morphine, providing a natural pharmacokinetic ceiling that prevents opioid accumulation in both organ-impaired compartments simultaneously
ANSWER: B
Rationale:
This question asked you to apply simultaneous renal and hepatic pharmacokinetic constraints to opioid selection in a treatment-naive cancer pain patient. Option B is correct. Fentanyl satisfies both constraints through a single metabolic mechanism: hepatic CYP3A4 (cytochrome P450 3A4)-mediated conversion to norfentanyl produces an inactive metabolite without meaningful renal clearance, directly eliminating the risk of renally toxic metabolite accumulation at eGFR 28 mL/min/1.73m² — the threshold below which morphine's M3G and M6G, and hydromorphone's H3G, accumulate to dangerous concentrations. The Child-Pugh Class B hepatic impairment does alter fentanyl pharmacokinetics and requires management: reduced CYP3A4 activity slows fentanyl clearance, extending its effective half-life; reduced first-pass extraction increases the oral bioavailability of any oral fentanyl formulation; and reduced alpha-1-acid glycoprotein synthesis increases the free fentanyl fraction. These hepatic effects are addressed by initiating at a conservative dose, titrating slowly, using extended intervals between dose adjustments, and monitoring for signs of accumulation — all feasible within fentanyl's pharmacokinetic framework. Buprenorphine would be an equally valid choice on the same mechanistic basis.
Option A: Option A is incorrect because morphine is contraindicated in eGFR 28 mL/min/1.73m²; dose reduction and interval extension do not prevent the accumulation of M3G (neuroexcitatory, pro-nociceptive) and M6G (potent MOR agonist causing respiratory depression) to toxic concentrations in significant renal impairment. These are qualitative metabolite toxicity concerns, not quantitative dose-reduction problems.
Option C: Option C is incorrect because hydromorphone's H3G metabolite is neuroexcitatory and pro-nociceptive — not analgesically active — and accumulates dangerously in renal impairment, causing myoclonus and cognitive toxicity rather than providing sustained analgesia. Hydromorphone is contraindicated in eGFR below 30 mL/min/1.73m² for this reason.
Option D: Option D is incorrect because while methadone's fecal excretion does confer theoretical renal safety, Child-Pugh Class B cirrhosis does meaningfully impair CYP3A4-mediated methadone metabolism and is not a threshold reserved for Class C only; methadone's complex pharmacokinetics, QTc prolongation risk, and drug interaction burden make it unsuitable as the default first opioid in an opioid-naive patient with dual organ impairment outside a specialist setting.
Option E: Option E is incorrect because codeine is contraindicated in both renal and hepatic impairment; reduced CYP2D6 activity does not provide a safe pharmacokinetic ceiling — it simply produces inadequate analgesia from codeine itself while the morphine metabolites that are produced accumulate in renal failure. In CYP2D6 poor metabolizers, codeine provides no analgesia; in normal metabolizers with renal impairment, the morphine produced accumulates toxically.
5. A 62-year-old woman with painful diabetic peripheral neuropathy (DPN) is on duloxetine 60 mg/day and pregabalin 300 mg/day with partial pain relief. Her pain specialist adds tapentadol extended-release 50 mg twice daily. Two days later she is admitted to hospital for a severe MRSA (methicillin-resistant Staphylococcus aureus) skin infection and started on linezolid 600 mg twice daily. On day 3 of linezolid therapy she develops agitation, diaphoresis, hyperreflexia, and a temperature of 38.9°C. Which of the following correctly identifies the drug interaction responsible for her presentation?
A) Linezolid inhibits CYP3A4, reducing tapentadol's hepatic clearance and causing tapentadol plasma concentrations to rise to toxic levels; the resulting mu-opioid receptor (MOR) overstimulation produces the autonomic instability and hyperthermia through a central opioid toxidrome rather than a serotonergic mechanism
B) Linezolid and duloxetine together inhibit renal tubular secretion of pregabalin, causing pregabalin accumulation that activates voltage-gated calcium channel alpha-2-delta subunits in the limbic system, producing the agitation and autonomic instability through a calcium channel-mediated central excitatory mechanism
C) Linezolid displaces duloxetine from plasma protein binding sites, acutely increasing the free duloxetine fraction and producing a transient surge in serotonin reuptake inhibition that overwhelms the serotonin transporter; the resulting acute serotonin excess produces the clinical picture, and protein binding equilibration will resolve the symptoms within 48 hours without medication changes
D) Duloxetine's serotonin reuptake inhibition combined with tapentadol's norepinephrine reuptake inhibition produces a pharmacodynamic interaction at noradrenergic synapses in the hypothalamus, causing dysregulated thermogenesis; this is a noradrenergic toxidrome rather than a serotonergic toxidrome, and treatment requires alpha-2 agonist therapy with clonidine rather than serotonin antagonism
E) Linezolid is a weak but clinically relevant inhibitor of monoamine oxidase (MAO); combined with duloxetine's serotonin reuptake inhibition and tapentadol's serotonin reuptake inhibition, the MAO inhibition by linezolid reduces the breakdown of synaptic serotonin — producing a triple serotonergic burden that exceeds the threshold for serotonin syndrome, manifesting as the classic triad of altered mental status, autonomic instability, and neuromuscular excitability
ANSWER: E
Rationale:
This question asked you to identify the drug interaction responsible for serotonin syndrome in a patient on multiple serotonergic agents started on linezolid. Option E is correct. Linezolid is an oxazolidinone antibiotic that is a weak but clinically meaningful monoamine oxidase (MAO) inhibitor — this property, shared with the related compound tedizolid, is not always prominent in prescribers' awareness but is well established and listed in the FDA prescribing information. By inhibiting MAO, linezolid reduces the synaptic breakdown of serotonin, norepinephrine, and dopamine. In this patient, three serotonergic mechanisms converge simultaneously: duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the serotonin transporter (SERT) and prevents synaptic serotonin reuptake; tapentadol also has serotonin reuptake inhibition activity (in addition to its predominantly noradrenergic mechanism and MOR agonism); and linezolid's MAO inhibition prevents the metabolic breakdown of the serotonin that has accumulated at the synapse. This triple burden — reduced reuptake from two agents plus reduced breakdown from linezolid — produces sufficient synaptic serotonin excess to cause serotonin syndrome, presenting with the classic triad of altered mental status (agitation), autonomic instability (diaphoresis, hyperthermia), and neuromuscular excitability (hyperreflexia). Management requires discontinuation of the serotonergic agents, supportive care, and consideration of cyproheptadine (a serotonin antagonist) for symptom control.
Option A: Option A is incorrect because linezolid is not a CYP3A4 inhibitor and does not elevate tapentadol concentrations through this mechanism; the presentation is serotonergic in character (hyperreflexia, agitation, hyperthermia), not a classical opioid toxidrome (miosis, respiratory depression, sedation).
Option B: Option B is incorrect because linezolid does not inhibit renal tubular secretion of pregabalin, and calcium channel alpha-2-delta subunit activation does not produce the described clinical syndrome; the serotonin syndrome diagnosis is supported by the clinical triad of agitation, autonomic instability, and hyperreflexia.
Option C: Option C is incorrect because linezolid does not produce clinically significant protein binding displacement of duloxetine; protein binding displacement interactions are rarely clinically meaningful, do not produce the sustained serotonin excess described, and would not generate the acute serotonin syndrome clinical picture.
Option D: Option D is incorrect because the clinical triad of agitation, hyperreflexia, and hyperthermia is characteristic of serotonin syndrome, not an isolated noradrenergic toxidrome; noradrenergic excess does contribute to the autonomic features of serotonin syndrome, but the full syndrome requires serotonergic excess as the primary driver, and clonidine does not address the underlying serotonergic mechanism.
6. A 77-year-old man with end-stage COPD and inoperable lung cancer is admitted to a palliative care unit with refractory dyspnea. He is on 4L/min supplemental oxygen with a resting respiratory rate of 28 breaths/minute and SpO2 of 86%. Despite maximal bronchodilator therapy and corticosteroids, his breathlessness is severe and distressing. He is opioid-naive. His family expresses concern that starting morphine will "speed up his death by stopping his breathing." His palliative care physician prepares to initiate low-dose morphine. Which of the following correctly characterizes the evidence base and the mechanism of action relevant to this family conversation?
A) The family's concern is pharmacologically valid — morphine at any dose produces dose-dependent respiratory depression that will measurably reduce minute ventilation and hasten death in a patient with SpO2 86% and RR 28; the physician should use non-opioid anxiolytics (lorazepam) alone for dyspnea management and reserve morphine for pain only, as its risk-benefit profile for dyspnea in this patient is unfavorable
B) Morphine is appropriate for dyspnea but the family should be informed that a small but real acceleration of death is an accepted ethical trade-off justified by the principle of double effect; hospice regulations require written acknowledgment from family that morphine for dyspnea may shorten survival by hours to days, distinguishing it legally from euthanasia
C) Morphine relieves dyspnea primarily by producing sedation at cortical levels, which reduces the patient's conscious awareness of breathlessness without affecting the underlying respiratory physiology; the family should be informed that the patient will be less aware of his breathing difficulty but that his respiratory rate and oxygenation will not change, and that sedation, not respiratory depression, is the desired therapeutic mechanism
D) Observational studies in hospice and palliative care consistently demonstrate that appropriately titrated opioids for dyspnea or pain at end of life do not shorten survival compared to matched controls not receiving opioids; morphine relieves dyspnea through mu-opioid receptor (MOR) activation in brainstem respiratory centers, reducing the central drive to breathe and the subjective perception of air hunger at doses lower than those required for analgesia — and relief of the subjective sensation occurs even when objective parameters such as respiratory rate and oxygen saturation remain unchanged; the ethical framework is the principle of double effect, but the clinical evidence shows that appropriately dosed opioids do not in fact hasten death
E) The family's concern is addressed by using fentanyl rather than morphine for dyspnea in this patient, because fentanyl's high lipophilicity produces faster CNS penetration and more rapid symptom relief before significant respiratory depression can develop; morphine's slower CNS penetration means it must be given at higher doses to achieve dyspnea relief, increasing the respiratory depression risk that the family is concerned about
ANSWER: D
Rationale:
This question asked you to apply the evidence base and mechanism for opioids in palliation of dyspnea to a family communication scenario. Option D is correct. The key clinical and ethical points the family needs to understand are: first, that appropriately titrated opioids for dyspnea at end of life do not shorten survival — observational studies in hospice and palliative care consistently show that patients receiving opioid infusions for dyspnea or pain have survival determined by their underlying disease trajectory, not by the opioid regimen; second, that the mechanism of morphine for dyspnea is MOR activation in brainstem respiratory centers that reduces both the physiological drive to breathe and the subjective perception of air hunger (breathlessness), at doses lower than those required for analgesia; and third, that the therapeutic endpoint is relief of the subjective distress of breathlessness, which occurs even when objective measurements (respiratory rate, SpO2) do not improve — the patient feels less distressed about his breathing even if it looks the same externally. The ethical framework of the principle of double effect — distinguishing intent to relieve suffering from intent to hasten death — provides ethical grounding, but the clinical evidence supports going further: appropriately dosed opioids do not in fact hasten death, removing the need for the double-effect trade-off reasoning in most cases.
Option A: Option A is incorrect because it overstates the respiratory risk of low-dose morphine for dyspnea in this setting; the clinical evidence directly contradicts the claim that morphine will measurably hasten death, and withholding opioids for dyspnea leaves a dying patient in preventable distress. Lorazepam alone does not adequately address the air hunger component of refractory dyspnea.
Option B: Option B is incorrect because it propagates the false premise that opioids shorten survival in palliative care — which the evidence does not support — and the claim that hospice regulations require written family acknowledgment of shortened survival from morphine for dyspnea is not accurate.
Option C: Option C is incorrect because while opioids do reduce the affective and perceptual component of breathlessness, the mechanism is brainstem MOR activation reducing respiratory drive, not purely cortical sedation; the description of sedation as the desired mechanism and the implication that respiratory physiology is entirely unaffected mischaracterizes the pharmacology and would provide an incomplete and misleading explanation to the family.
Option E: Option E is incorrect because fentanyl versus morphine selection for dyspnea is not determined by lipophilicity-mediated safety differentiation; both agents are appropriate for dyspnea in palliative care settings, and the mechanism-based explanation in Option D applies to both; the clinical concern the family raised is addressed by evidence and mechanism, not by opioid switching.
7. A 59-year-old woman with chronic neuropathic low back pain is well controlled on oxycodone extended-release 40 mg twice daily. She is seen by neurology for new trigeminal neuralgia and started on carbamazepine 200 mg twice daily, titrated to 400 mg twice daily over three weeks. During this period she reports progressively worsening back pain returning to pre-treatment severity, despite taking her oxycodone doses reliably. Serum oxycodone levels obtained at steady state are substantially below the therapeutic range established on her prior dose. Which of the following most accurately explains her worsening pain control?
A) Carbamazepine is a potent inducer of CYP3A4 (cytochrome P450 3A4), the primary enzyme responsible for oxycodone metabolism; CYP3A4 induction dramatically accelerates oxycodone clearance, reducing its plasma concentrations below the therapeutic range despite unchanged dosing — the same pharmacokinetic mechanism responsible for carbamazepine's interactions with multiple other CYP3A4-substrate drugs; the appropriate response is to increase the oxycodone dose while carbamazepine therapy continues, or to consider an alternative opioid less susceptible to CYP3A4 induction, or to reconsider the anticonvulsant choice
B) Carbamazepine directly antagonizes mu-opioid receptors (MOR) in the spinal dorsal horn through a sodium channel-independent mechanism; as carbamazepine plasma concentrations reach therapeutic levels, progressive MOR antagonism reduces oxycodone's analgesic efficacy despite normal plasma oxycodone concentrations; this pharmacodynamic interaction explains the low measured oxycodone levels as a consequence of reduced MOR activation rather than reduced drug exposure
C) Carbamazepine inhibits P-glycoprotein (P-gp) efflux at the blood-brain barrier, paradoxically reducing central nervous system oxycodone penetration despite normal peripheral plasma concentrations; the low measured oxycodone levels reflect the technique artifact of sampling venous blood rather than CNS drug concentrations, and true CNS oxycodone exposure is normal; the worsening pain reflects disease progression rather than a drug interaction
D) Carbamazepine inhibits CYP2D6-mediated conversion of oxycodone to oxymorphone, reducing the active metabolite responsible for oxycodone's analgesic effect; because oxycodone itself is pharmacologically inactive and requires CYP2D6 activation to oxymorphone for all of its analgesia, the CYP2D6 inhibition by carbamazepine produces complete loss of opioid analgesia; the appropriate response is to switch to morphine, which does not require CYP2D6 activation
E) Carbamazepine produces pharmacodynamic tolerance to opioid analgesia by upregulating sodium channel expression in dorsal horn neurons, which increases the depolarization threshold and reduces the sensitivity of opioid-modulated pain transmission circuits to MOR agonism; the appropriate response is to add a second opioid with a different receptor profile (such as buprenorphine) to overcome the sodium channel-mediated tolerance
ANSWER: A
Rationale:
This question asked you to identify the pharmacokinetic mechanism responsible for reduced oxycodone efficacy after carbamazepine initiation. Option A is correct. Carbamazepine is one of the most potent CYP3A4 inducers in clinical use, acting through activation of the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) to dramatically upregulate CYP3A4 expression in the liver and intestinal wall. Oxycodone is primarily metabolized by CYP3A4 (to noroxycodone, the major metabolite) and secondarily by CYP2D6 (to oxymorphone, the active metabolite). CYP3A4 induction by carbamazepine accelerates oxycodone's primary metabolic clearance, reducing plasma oxycodone concentrations below therapeutic levels despite unchanged dosing — directly explaining the low measured oxycodone levels and the return of pain. The time course of worsening over three weeks corresponds to the progressive upregulation of CYP3A4 as carbamazepine is titrated, consistent with the mechanism. Management options include increasing the oxycodone dose to compensate for accelerated clearance, switching to a less CYP3A4-dependent opioid (such as hydromorphone or, with caution, methadone — which is also CYP3A4-dependent but may have different susceptibility), or reconsidering whether carbamazepine is necessary for the trigeminal neuralgia (oxcarbazepine, another voltage-gated sodium channel blocker, is also a CYP3A4 inducer; gabapentin or pregabalin would not carry this interaction).
Option B: Option B is incorrect because carbamazepine does not directly antagonize MOR through any mechanism; its analgesic and anticonvulsant mechanism is voltage-gated sodium channel blockade, not opioid receptor antagonism. Low measured oxycodone plasma levels confirm the pharmacokinetic explanation, not a pharmacodynamic one.
Option C: Option C is incorrect because carbamazepine does not inhibit P-gp at the blood-brain barrier; carbamazepine is actually a P-gp inducer. Additionally, the low measured venous oxycodone concentrations are real, not a sampling artifact, and directly explain the reduced analgesic effect.
Option D: Option D is incorrect because oxycodone is not a pharmacologically inactive prodrug requiring CYP2D6 activation for all of its analgesia; oxycodone itself has direct and meaningful MOR agonist activity independent of its CYP2D6-mediated conversion to oxymorphone, and carbamazepine is a CYP3A4 inducer, not a CYP2D6 inhibitor.
Option E: Option E is incorrect because carbamazepine does not upregulate dorsal horn sodium channels to produce opioid tolerance through a pharmacodynamic mechanism; the established interaction is pharmacokinetic CYP3A4 induction, and the low measured plasma oxycodone levels confirm reduced drug exposure rather than a pharmacodynamic desensitization.
8. A 44-year-old man with opioid use disorder (OUD) maintained on buprenorphine-naloxone 24 mg/day undergoes emergency appendectomy. In the post-operative period he rates his surgical pain 9/10 and is placed on a morphine patient-controlled analgesia (PCA) pump. After two hours he has delivered 22 PCA doses with no analgesic effect. His vital signs are stable; he appears in genuine distress without any signs of opioid toxicity. Which of the following correctly explains the PCA failure and identifies the most appropriate acute management strategy?
A) The PCA morphine is failing because buprenorphine-naloxone contains naloxone, which absorbed sublingually has produced systemic MOR antagonism at sufficient plasma concentrations to block all morphine analgesia; the correct management is to discontinue buprenorphine-naloxone and switch to buprenorphine monoproduct before resuming the morphine PCA
B) The PCA morphine is failing because the patient has developed complete opioid tolerance from chronic buprenorphine exposure, requiring morphine doses 10–20 times the standard PCA bolus to overcome the tolerance; the correct management is to increase the PCA bolus dose to 20–30 mg and reduce the lockout interval to 5 minutes to achieve adequate post-operative analgesia
C) Buprenorphine's exceptionally high MOR affinity and slow receptor dissociation kinetics mean that it occupies the majority of available MOR at the 24 mg/day maintenance dose, preventing morphine from accessing sufficient receptor population to produce analgesia; the most appropriate acute management strategy includes continuing buprenorphine (to prevent OUD relapse risk from withdrawal), adding high-dose full MOR agonist analgesia with close monitoring, supplementing with non-opioid multimodal analgesics (NSAIDs, ketamine, regional anesthesia if feasible), and involving addiction medicine and acute pain specialists
D) The PCA failure results from morphine-buprenorphine pharmacokinetic interaction at the hepatic CYP3A4 level; buprenorphine induces CYP3A4, dramatically accelerating morphine metabolism to M3G and M6G before morphine can exert its analgesic effect; the correct management is to switch from morphine PCA to fentanyl PCA, as fentanyl's CYP3A4 metabolism is not accelerated by buprenorphine induction
E) The PCA morphine is failing because buprenorphine's partial MOR agonism at 24 mg/day has produced maximal receptor phosphorylation and beta-arrestin recruitment, causing receptor internalization that persists for 48–72 hours after the last buprenorphine dose; the correct management is to withhold buprenorphine for 48 hours before administering any full MOR agonist, allowing receptor resurfacing to restore morphine responsiveness
ANSWER: C
Rationale:
This question asked you to explain PCA morphine failure in a buprenorphine-maintained patient and identify appropriate acute surgical pain management. Option C is correct. Buprenorphine has the highest MOR affinity among clinically used opioids and exhibits slow receptor dissociation kinetics — meaning it binds tightly to MOR and releases slowly. At the 24 mg/day maintenance dose, buprenorphine occupies the vast majority of available MOR, leaving insufficient free receptor for morphine to bind in quantities necessary to produce clinically meaningful analgesia. This is a pharmacodynamic receptor competition phenomenon: morphine's lower MOR affinity means it cannot effectively displace buprenorphine from receptor binding sites at standard PCA doses. The acute surgical pain management strategy for buprenorphine-maintained patients requires a multimodal approach: continuing buprenorphine at the maintenance dose (abrupt discontinuation risks OUD relapse and precipitates withdrawal, which compounds the pain burden); adding full MOR agonist opioids at higher-than-standard doses with close monitoring for the partial analgesia that can be achieved above buprenorphine's receptor occupancy; aggressively supplementing with non-opioid analgesics (NSAIDs, acetaminophen, ketamine, dexamethasone); and using regional anesthesia (epidural, nerve blocks) where surgically feasible to provide opioid-independent analgesia. Addiction medicine consultation is essential.
Option A: Option A is incorrect because naloxone in sublingual buprenorphine-naloxone formulations has very poor sublingual bioavailability by design; the systemic naloxone concentrations after sublingual buprenorphine-naloxone are negligible and do not produce clinically meaningful systemic MOR antagonism. The PCA failure is a pharmacodynamic buprenorphine-morphine receptor competition phenomenon, not a naloxone antagonism phenomenon.
Option B: Option B is incorrect because "complete opioid tolerance requiring 10–20 times standard doses" mischaracterizes the mechanism; the problem is pharmacodynamic receptor blockade by buprenorphine's high-affinity occupancy, not classic MOR downregulation tolerance. Increasing the PCA bolus to 20–30 mg with a 5-minute lockout creates serious respiratory depression risk when buprenorphine's MOR occupancy eventually changes.
Option D: Option D is incorrect because buprenorphine does not induce CYP3A4 and does not accelerate morphine metabolism; the mechanism of PCA failure is pharmacodynamic receptor competition, not pharmacokinetic drug interaction.
Option E: Option E is incorrect because withholding buprenorphine for 48 hours in a patient with active OUD creates an unacceptable risk of OUD relapse and acute opioid withdrawal, and the receptor resurfacing timeline cited is not clinically validated as a management strategy; current evidence and addiction medicine guidelines favor continuing buprenorphine through the acute surgical pain episode.
9. A 66-year-old woman with postherpetic neuralgia (PHN) affecting the left V2 trigeminal distribution has failed gabapentin, pregabalin, and amitriptyline. She has stage 3b chronic kidney disease (eGFR 33 mL/min/1.73m²) and describes her pain as having a prominent affective quality — a deep, relentless unpleasantness she finds more distressing than the intensity itself. Her clinician considers oxycodone extended-release versus transdermal buprenorphine as the next step. Which of the following correctly identifies the two pharmacological properties that make transdermal buprenorphine the more appropriate choice for this specific patient?
A) Buprenorphine is preferred because its partial mu-opioid receptor (MOR) agonism produces a ceiling effect for analgesia that limits dose escalation and prevents the development of opioid tolerance, and because its high lipophilicity makes it uniquely suitable for transdermal delivery in elderly patients with unpredictable gastrointestinal absorption; oxycodone's full MOR agonism and oral formulation are both disadvantages in this population
B) Buprenorphine is preferred for two reasons specific to this patient: first, its pharmacokinetic profile in renal impairment is favorable because its metabolic products do not accumulate to toxic concentrations as eGFR declines — directly addressing her eGFR 33 mL/min/1.73m² — unlike oxycodone, whose active metabolites accumulate in renal impairment; second, buprenorphine's intrinsic kappa-opioid receptor (KOR) antagonism at therapeutic doses may reduce the dysphoric and affective burden of neuropathic pain, which she has specifically identified as her predominant source of distress, through a mechanism distinct from MOR-mediated analgesia
C) Buprenorphine is preferred because it has N-methyl-D-aspartate (NMDA) receptor antagonist properties equivalent to methadone, directly targeting the central sensitization component of PHN that has failed to respond to gabapentinoids; oxycodone lacks NMDA antagonism and is therefore mechanistically inferior for neuropathic pain of central sensitization origin
D) Buprenorphine is preferred because its extremely long half-life of 72–96 hours in elderly patients allows once-weekly transdermal dosing that improves adherence compared to twice-daily oxycodone extended-release; the reduced dosing frequency is the primary pharmacokinetic advantage in this age group, and the renal profile and receptor pharmacology are secondary considerations
E) Buprenorphine is preferred because it is the only opioid approved by the FDA specifically for neuropathic pain, having undergone regulatory review for postherpetic neuralgia and diabetic peripheral neuropathy as labeled indications; oxycodone carries no FDA indication for neuropathic pain and its use in PHN is therefore off-label, representing a regulatory rather than pharmacological disadvantage
ANSWER: B
Rationale:
This question asked you to identify the two specific pharmacological properties that make transdermal buprenorphine preferable to oxycodone in this elderly patient with PHN, renal impairment, and a predominantly affective pain quality. Option B is correct on both counts. First, buprenorphine's renal safety: buprenorphine's primary metabolic products — buprenorphine-3-glucuronide and norbuprenorphine glucuronide — do not accumulate to dangerous concentrations as eGFR declines, making it a safe opioid choice at eGFR 33 mL/min/1.73m². Oxycodone, in contrast, produces active metabolites including oxymorphone and noroxycodone that accumulate in renal impairment, increasing the risk of opioid toxicity as the patient's kidney function continues to decline. Second, buprenorphine's KOR antagonism: at therapeutic doses, buprenorphine is an intrinsic antagonist at kappa-opioid receptors (KOR). KOR activation in the spinal cord and supraspinal circuits is associated with the dysphoric, aversive, and affectively unpleasant quality of chronic pain — precisely the quality this patient has identified as her primary burden. Buprenorphine's KOR antagonism may attenuate this affective dimension of her neuropathic pain independently of its MOR partial agonist analgesia, providing a mechanistic rationale specific to her symptom profile. The transdermal patch (Butrans) provides continuous low-dose delivery appropriate for stable neuropathic pain.
Option A: Option A is incorrect because while buprenorphine's partial MOR agonism and transdermal delivery are real properties, the clinical reasoning given — that the ceiling effect is advantageous and gastrointestinal absorption is uniquely unpredictable in elderly patients — does not represent the pharmacologically specific reasons favoring buprenorphine over oxycodone in this patient's context. The ceiling effect for analgesia is as much a limitation as an advantage.
Option C: Option C is incorrect because buprenorphine does not have NMDA receptor antagonist properties; NMDA antagonism is a property of methadone and levorphanol, not buprenorphine.
Option D: Option D is incorrect because transdermal buprenorphine patches (Butrans) are designed for weekly application (7-day patch), not once-weekly based on a 72–96 hour half-life; the half-life figure is inaccurate, and while improved adherence from transdermal delivery is a real advantage, it is not the primary pharmacological reason to prefer buprenorphine over oxycodone in this patient.
Option E: Option E is incorrect because buprenorphine does not carry specific FDA labeling for PHN or DPN as neuropathic pain indications; its use in neuropathic pain is supported by evidence but is not uniquely FDA-approved for these conditions in a manner that disadvantages oxycodone on regulatory grounds.
10. A 31-year-old man is found unresponsive in a public restroom. Bystanders administer naloxone 2 mg intramuscularly from a community kit. He regains consciousness within 3 minutes, is alert and oriented, and refuses transport to hospital. He is discharged on scene by emergency medical services after 15 minutes of observation. Forty-five minutes later he is found unresponsive again and is transported by ambulance; he requires three additional naloxone doses over the next two hours to maintain adequate ventilation. Illicitly manufactured fentanyl (IMF) is confirmed on urine toxicology. Which of the following best explains his clinical course and identifies the critical management error?
A) The recurrent unresponsiveness reflects a second, separate fentanyl exposure after the initial reversal — a common pattern in opioid use disorder where individuals resume drug use immediately after reversal; the management error was failure to confiscate the patient's remaining drug supply at the scene, which is now a standard of care requirement for community naloxone programs
B) The recurrent unresponsiveness reflects naloxone-induced acute opioid withdrawal, which produces a catecholamine surge that initially appears as arousal but causes delayed cardiovascular collapse and loss of consciousness 30–60 minutes after administration; the management error was using 2 mg naloxone rather than the recommended 0.4 mg titrated dose, which produces less severe withdrawal and avoids the delayed collapse
C) The recurrent unresponsiveness reflects fentanyl's conversion to an active toxic metabolite (norfentanyl) over 30–60 minutes after initial exposure; naloxone reversed the parent fentanyl effect but norfentanyl — which naloxone does not antagonize — accumulated during this period and produced the second episode of respiratory depression; the management error was failure to administer a naloxone infusion targeting the norfentanyl accumulation window
D) Fentanyl's high lipophilicity drives rapid CNS penetration causing the initial overdose, but naloxone's effective duration of action (approximately 45–90 minutes at standard doses) is shorter than the duration over which fentanyl can sustain clinically significant CNS concentrations through redistribution from peripheral tissue compartments back into plasma and CNS; the resedation 45 minutes after apparent recovery represents fentanyl redistribution-driven recurrence of MOR activation after naloxone's competitive blockade waned; the critical management error was discharging the patient after 15 minutes of observation — IMF overdose requires a minimum observation period of several hours in a monitored medical setting due to the high resedation risk
E) The recurrent unresponsiveness reflects the naloxone autoinjector's intramuscular pharmacokinetics, which produce a biphasic plasma concentration profile with a secondary absorption peak at 45–60 minutes that paradoxically antagonizes endogenous opioid peptides (endorphins and enkephalins) responsible for maintaining consciousness; the management error was using an intramuscular rather than intranasal formulation, which produces a smoother concentration-time profile without the secondary peak
ANSWER: D
Rationale:
This question asked you to explain fentanyl resedation after apparent naloxone reversal and identify the management error. Option D is correct. Fentanyl's high lipophilicity drives extremely rapid CNS penetration after exposure — producing fast-onset respiratory depression — and equally rapid redistribution from the CNS into peripheral lipid-rich tissues (fat, muscle) as plasma concentrations fall. After naloxone reverses the initial CNS fentanyl effect, the competitive MOR blockade provided by naloxone is time-limited: at standard doses, naloxone's effective duration of receptor blockade is approximately 45–90 minutes. During this window the patient appears aroused and functional. However, fentanyl continues to recirculate from peripheral tissue compartments back into plasma (redistribution) as the plasma-tissue concentration gradient re-equilibrates, and as naloxone's competitive blockade wanes, the redistributed fentanyl re-enters the CNS and reactivates MOR — producing the second episode of respiratory depression 45 minutes after apparent recovery. In illicitly manufactured fentanyl exposures, the total fentanyl dose in a typical exposure may be substantial given IMF's extreme potency, making resedation particularly likely. The critical management error was discharge after only 15 minutes of observation. IMF overdose survivors require monitoring in a medical setting for a minimum of several hours — often 4–8 hours — because resedation risk persists well beyond the initial reversal period. Repeat naloxone dosing, higher naloxone doses, or a continuous naloxone infusion titrated to respiratory response are appropriate for sustained fentanyl effects.
Option A: Option A is incorrect because while re-exposure to drugs after reversal does occur, the time course of 45 minutes after a confirmed response to naloxone in a monitored patient is more consistent with pharmacokinetic resedation than with a discrete new exposure; the management error was premature discharge, not failure to confiscate drugs, which is not a standard of care requirement.
Option B: Option B is incorrect because naloxone does not cause delayed cardiovascular collapse; acute opioid withdrawal from naloxone produces agitation, diaphoresis, tachycardia, and nausea — not delayed loss of consciousness 30–60 minutes later. The 2 mg dose may cause more pronounced withdrawal symptoms than titrated lower doses but does not cause the clinical pattern described.
Option C: Option C is incorrect because norfentanyl is an inactive metabolite — it has no clinically meaningful MOR agonist activity and does not produce respiratory depression; naloxone does not need to antagonize norfentanyl because norfentanyl has no opioid effect.
Option E: Option E is incorrect because intramuscular naloxone does not produce a clinically meaningful biphasic absorption peak that antagonizes endogenous opioid peptides to cause loss of consciousness; this mechanism is pharmacologically unsupported, and endorphin/enkephalin antagonism by naloxone at standard doses does not produce unconsciousness in non-opioid-dependent patients.
11. A 52-year-old woman completed six cycles of oxaliplatin-based chemotherapy for stage III colon cancer eight months ago. She has persistent bilateral distal lower extremity numbness, burning pain, and cold allodynia rated 7/10 that significantly limits her function. She was treated with duloxetine 60 mg/day for four months with minimal benefit and discontinued it due to nausea. Her oncologist is now considering adding an opioid for ongoing pain management. Which of the following most accurately characterizes the evidence base for opioids in chemotherapy-induced peripheral neuropathy (CIPN) and the mechanistic basis for their limited efficacy in this condition?
A) Opioids are the preferred second-line treatment for CIPN after duloxetine failure, endorsed by the American Society of Clinical Oncology (ASCO) as the agent class with the strongest evidence for CIPN pain after first-line failure; their efficacy in CIPN is comparable to their efficacy in postherpetic neuralgia (PHN), and dose escalation to full analgesic doses is expected to achieve clinically meaningful relief in the majority of patients
B) Opioids are contraindicated in CIPN because mu-opioid receptor (MOR) agonism paradoxically activates the same protein kinase C (PKC) pathways through which platinum compounds cause dorsal root ganglion (DRG) neuronal injury, potentially worsening the underlying neuropathy with each dose; ASCO guidelines explicitly prohibit opioid use in CIPN for this reason
C) Opioids have no role in CIPN management because CIPN pain is mediated exclusively through large-fiber A-beta mechanoreceptors, which express no MOR at their central terminals in the dorsal horn; MOR agonists therefore have no spinal target relevant to CIPN pain and produce no analgesic effect regardless of dose
D) Strong opioids are first-line for CIPN in patients who have failed duloxetine because the DRG neuronal injury pattern of platinum compounds specifically upregulates spinal MOR expression, making CIPN one of the pain conditions where opioids have superior efficacy compared to their performance in other neuropathic pain types; ASCO endorses this evidence base
E) Opioids have no specific evidence of superiority over non-opioid analgesics in CIPN and are used empirically for refractory cases after failure of agents with stronger evidence; the limited opioid responsiveness likely reflects the preferential DRG neuronal injury pattern of oxaliplatin and other platinum compounds — which damages sensory neuron cell bodies in the dorsal root ganglion through DNA adduct formation — producing a dying-back neuropathy that is less amenable to modulation by spinal and supraspinal MOR circuits than peripheral sensitization or dorsal horn-level nociceptive processing
ANSWER: E
Rationale:
This question asked you to characterize the evidence base for opioids in CIPN and explain the mechanism of their limited efficacy. Option E is correct. Among pharmacological treatments for CIPN, duloxetine is the only agent with randomized controlled trial evidence supporting moderate efficacy and is the ASCO-endorsed preferred treatment. After duloxetine failure, there is no agent class with strong RCT-level CIPN-specific evidence; opioids are used empirically for refractory cases but have not demonstrated superiority over non-opioid analgesics in CIPN-specific studies. The mechanistic explanation for limited opioid responsiveness in CIPN is distinct from other neuropathic pain conditions: platinum compounds (cisplatin, oxaliplatin, carboplatin) cause DNA adduct formation preferentially in dorsal root ganglion (DRG) neuronal cell bodies — the sensory neuron soma — leading to a dying-back neuropathy in which peripheral sensory fibers degenerate centrifugally from the cell body outward. This DRG-level neuronal injury pattern differs from the peripheral sensitization of intact nociceptors (which drives nociceptive and some inflammatory pain) and from the dorsal horn central sensitization that MOR agonists modulate most effectively at the presynaptic and postsynaptic spinal level. Pain maintained by pathological reorganization at the DRG neuronal cell body level may be less responsive to opioid modulation of downstream spinal and supraspinal circuits, explaining the limited clinical efficacy. Opioids remain a reasonable empirical option for refractory CIPN pain where quality of life is severely impacted and other options have been exhausted, but with realistic expectations of partial rather than complete relief.
Option A: Option A is incorrect because ASCO does not endorse opioids as the preferred second-line treatment after duloxetine failure in CIPN with evidence comparable to PHN; opioid evidence in CIPN is specifically weaker and less well-established than in PHN.
Option B: Option B is incorrect because opioids are not contraindicated in CIPN for the PKC pathway reason described; MOR agonism does not activate platinum-type DNA adduct-forming PKC pathways, and ASCO guidelines do not explicitly prohibit opioid use in CIPN.
Option C: Option C is incorrect because CIPN pain is not mediated exclusively through large-fiber A-beta mechanoreceptors; small-fiber C fiber and A-delta fiber damage is central to CIPN pathophysiology, and MOR is expressed at the central terminals of these fibers in the dorsal horn.
Option D: Option D is incorrect because platinum compound-induced DRG injury does not upregulate spinal MOR expression in a manner that makes opioids more effective in CIPN than in other neuropathic conditions; the opposite is closer to the clinical reality — the DRG injury pattern makes opioid responsiveness less predictable in CIPN.
QUESTION ANSWER KEY
Q1: D | Q2: A | Q3: C | Q4: B | Q5: E | Q6: D | Q7: A | Q8: C | Q9: B | Q10: D | Q11: E
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.